Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
Clin Res Hepatol Gastroenterol
    May 2026
  1. PENG L, Dai Y
    Prevalence of anti-mitochondrial antibodies and clinical features in autoimmune hepatitis (AIH) patients.
    Clin Res Hepatol Gastroenterol. 2026;50:102810.
    >> Share

    April 2026
  2. HOEMANN BL, Kollef MH, Vijayan A, Michelson AP, et al
    Predictors of in-hospital mortality among patients with cirrhosis and renal replacement therapy in the ICU: a retrospective cohort study.
    Clin Res Hepatol Gastroenterol. 2026 Apr 1:102821.
    >> Share

  3. ESPEROUZ F, Villani R, Ciavarella D, Serviddio G, et al
    How do oral pathogenic bacteria potentially contribute to inflammatory processes in autoimmune liver disease? Results from a systematic review.
    Clin Res Hepatol Gastroenterol. 2026;50:102797.
    >> Share

    March 2026
  4. MOKKAPATI A, Thakkar R, Rani A, Puri D, et al
    Comment on "Sequential Anticoagulation with LMWH and DOACs in Cirrhotic Portal Vein Thrombosis".
    Clin Res Hepatol Gastroenterol. 2026 Mar 10:102806.
    >> Share

  5. CHODNICKA P, Jurkiewicz E, Janowski K, Janowska M, et al
    Sensitivity and specificity of magnetic resonance elastography in liver diseases in the pediatric age group.
    Clin Res Hepatol Gastroenterol. 2026;50:102768.
    >> Share

    February 2026
  6. ONAY M, Heilani M, Gulia C, Matthias C, et al
    Sequential Anticoagulation with LMWH and DOACs in Cirrhotic Portal Vein Thrombosis.
    Clin Res Hepatol Gastroenterol. 2026 Feb 23:102792.
    >> Share

  7. BEYENE E, Chirumamilla L, Bisrat M, Bowen A, et al
    Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction-associated steatohepatitis (MASH): A real-world data analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102760.
    >> Share

  8. DING C, Xing Y, Liang S, Wang C, et al
    Rifaximin for Primary prophylaxis of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A cohort analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102751.
    >> Share

    January 2026
  9. DONGIER A, Louis E, Loly JP, Dandoy P, et al
    QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study.
    Clin Res Hepatol Gastroenterol. 2026 Jan 26:102776.
    >> Share

    December 2025
  10. TIROTTA D, Lena C, Torre M, Muratori P, et al
    Hematologic Focal Hepatic Lesions in the Absence of Liver Cirrhosis: Consider Lymphoma and Myeloma.
    Clin Res Hepatol Gastroenterol. 2025 Dec 16:102749.
    >> Share

  11. LEPOUR M, Delorme A, Goffaux A, Trefois P, et al
    Low muscle density and Five Times Sit-to-Stand Test predict poor outcome in liver transplant candidates.
    Clin Res Hepatol Gastroenterol. 2025 Dec 10:102743.
    >> Share

  12. MARTINEZ-SANCHEZ FD, Agurre-Villarreal D, Argaiz ER, Rosales-Renteria LA, et al
    Physiology-Guided Albumin Therapy in Decompensated Cirrhosis: The Expanding Role of Point-of-Care Ultrasound.
    Clin Res Hepatol Gastroenterol. 2025 Dec 9:102744.
    >> Share

    October 2025
  13. MARYAM A, Naghshzan A, Mahmood H, Mohsen D, et al
    Cirrhotic Cardiomyopathy in Children: A Comprehensive Assessment Using ECG, Echocardiography, and NT-Pro-BNP.
    Clin Res Hepatol Gastroenterol. 2025 Oct 28:102721.
    >> Share

    September 2025
  14. HAIDER S
    Proton Pump Inhibitors Versus H2-Receptor Antagonists in Cirrhotic Patients: A Clinical Case and Literature Perspective.
    Clin Res Hepatol Gastroenterol. 2025 Sep 2:102681.
    >> Share

  15. HEXNER-ERLICHMAN Z, Assy N, Habashi N, Yousif A, et al
    Multiorgan fibrosis in Gaucher disease type I: an unmet goal of enzyme replacement therapy.
    Clin Res Hepatol Gastroenterol. 2025;49:102677.
    >> Share

  16. RATTANAPITOON NK, La N, Rattanapitoon SK
    Reconsidering the post-SVR landscape: Clinical implications of rising steatosis despite fibrosis regression.
    Clin Res Hepatol Gastroenterol. 2025;49:102661.
    >> Share

    August 2025
  17. SOPHASATH M, Tremblay M, Hogue C, Brisset A, et al
    Evaluation of a nutritional education guide designed for patients living with cirrhosis: A randomized controlled mixed-methods study.
    Clin Res Hepatol Gastroenterol. 2025;49:102672.
    >> Share

  18. JABER H, Chehayeb S, Nasr J, Souky NA, et al
    Proton Pump Inhibitor Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2025 Aug 12:102667.
    >> Share

    July 2025
  19. BROWN C
    A call for increased advocacy and universal resources to support effective nutritional interventions in the comprehensive management of patients with cirrhosis.
    Clin Res Hepatol Gastroenterol. 2025;49:102650.
    >> Share

  20. SUALEHEEN A, Tan SY, Daly RM, Georgousopoulou E, et al
    Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population.
    Clin Res Hepatol Gastroenterol. 2025;49:102649.
    >> Share

  21. XU L, Yin B, Chen D, Xiong X, et al
    Specific association and independent predictive value of HBV RNA in the disease progression of hepatitis B with low-level viremia.
    Clin Res Hepatol Gastroenterol. 2025;49:102648.
    >> Share

  22. CARRIER P, Chalange M, Girard M, Premaud A, et al
    Liver fibrosis evaluation in patients with psychiatric diseases.
    Clin Res Hepatol Gastroenterol. 2025;49:102636.
    >> Share

  23. XU X, Zhao H, Zhang J, Yan H, et al
    Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations.
    Clin Res Hepatol Gastroenterol. 2025;49:102617.
    >> Share

    June 2025
  24. SHENGIR M, Elgretli W, Cinque F, Ramanakumar AV, et al
    Metabolic Factors Drive Early Increase in Hepatic Steatosis Despite Improvement in Non-Invasive Fibrosis Markers after Hepatitis C Eradication with Direct-Acting Antivirals.
    Clin Res Hepatol Gastroenterol. 2025 Jun 16:102639.
    >> Share

  25. BEN YEDDER N, Girot P, Koudougou C, Schnee M, et al
    Lack of prior screening for advanced liver fibrosis in patients with newly diagnosed hepatocellular carcinoma: Results from a prospective multicentre study.
    Clin Res Hepatol Gastroenterol. 2025;49:102607.
    >> Share

  26. GOYAL RM, Bansal B, Ayyad M, Singh A, et al
    Clinical outcomes in patients with autoimmune hepatitis and primary biliary cholangitis overlap syndrome in the United States.
    Clin Res Hepatol Gastroenterol. 2025;49:102598.
    >> Share

    May 2025
  27. KARIYAMA K, Toyoda H, Kumada T, Yasuda S, et al
    Utility of the Fibrosis-3 Index for Predicting Liver Fibrosis 5 Years After Achieving Sustained Virological Response in Patients with Chronic Hepatitis C.
    Clin Res Hepatol Gastroenterol. 2025 May 27:102625.
    >> Share

  28. LEE CH, Kang MG, Oh S, Gwak IS, et al
    Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study.
    Clin Res Hepatol Gastroenterol. 2025;49:102612.
    >> Share

  29. VILLAVICENCIO EA, Serdjebi C, Maldonado A, Ochoa Mora E, et al
    Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting.
    Clin Res Hepatol Gastroenterol. 2025;49:102581.
    >> Share

    April 2025
  30. TATOUR M, Baker FA, Saadi T, Yahia A, et al
    Advancements in autoimmune hepatitis epidemiology, treatment and complication - a 15-year retrospective study.
    Clin Res Hepatol Gastroenterol. 2025;49:102570.
    >> Share

  31. LANTHIER N, Spahr L
    Macrophage therapy and liver regeneration: Results and perspectives.
    Clin Res Hepatol Gastroenterol. 2025;49:102569.
    >> Share

    March 2025
  32. HE Y, Ye M, Xia Y, Zhong Z, et al
    The role of cytokines as predictors for NAFLD-related diseases: A bidirectional Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2025;49:102545.
    >> Share

  33. ABDEL MONEM MS, Adel A, Abbassi MM, Abdelaziz DH, et al
    Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.
    Clin Res Hepatol Gastroenterol. 2025;49:102543.
    >> Share

    February 2025
  34. LIU Z, Yang X, Jiang H, Xie R, et al
    Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis.
    Clin Res Hepatol Gastroenterol. 2025 Feb 19:102553.
    >> Share

    January 2025
  35. SASAKI M, Sato Y, Nakanuma Y
    A heterogeneous subtype of biliary epithelial senescence may be involved in the pathogenesis of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2025;49:102512.
    >> Share

    November 2024
  36. WANG Z, Wang Z, Li F, Cai J, et al
    Construction and Validation of a Machine Learning-Based Prediction Model for Short-Term Mortality in Critically Ill Patients with Liver Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 30:102507.
    >> Share

  37. JIANG J, Bouquet E, Kweon Y, Elsaid MI, et al
    Neighborhood Opportunity is Associated with Completion of Hepatocellular Carcinoma Surveillance Prior to the Diagnosis of Hepatocellular Carcinoma in Patients with Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 1:102485.
    >> Share

  38. LEE YP, Chiu CC, Chang YC, Chen YH, et al
    Co-exposure to different bacterial species' lipopolysaccharides with the NASH diet exacerbates NASH and liver fibrosis progression in mice.
    Clin Res Hepatol Gastroenterol. 2024;48:102470.
    >> Share

    October 2024
  39. ZHONG H, Lu S, Xu M, Liu N, et al
    Predictive value of hepatic venous pressure gradient in cirrhotic portal vein thrombosis development.
    Clin Res Hepatol Gastroenterol. 2024 Oct 29:102484.
    >> Share

  40. DING J, He X, Lin W, Xia S, et al
    Exploring the relationship between vitamin D and hepatic carcinoma in individuals diagnosed with hepatitis B virus infection.
    Clin Res Hepatol Gastroenterol. 2024;48:102457.
    >> Share

  41. CANCADO GGL, Fucuta PDS, Gomes NMF, Couto CA, et al
    Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102453.
    >> Share

  42. WANG M, Liu X, Qiao C, Chen R, et al
    Association of congenital hepatic fibrosis and Caroli's syndrome: Two illustrative cases.
    Clin Res Hepatol Gastroenterol. 2024;48:102443.
    >> Share

  43. KHONDE P, Choudhury S, Spies NC, Naz N, et al
    Worse fibro-inflammatory activity on diagnostic liver biopsy adversely impacts biochemical remission in autoimmune hepatitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102442.
    >> Share

    September 2024
  44. HAO NB, Zhou Y, Zhang D, Li YN, et al
    Effect of sarcopenia on liver cirrhosis with complicating oesophageal and gastric varices after endoscopic therapy.
    Clin Res Hepatol Gastroenterol. 2024 Sep 10:102459.
    >> Share

  45. KURNIAWAN J, Siahaan BS
    Performance of Spleen Stiffness Measurement by 100-Hz Vibration-Controlled Transient Elastography, Liver Stiffness, APRI Score and their Combination for Predicting Oesophageal Varices in Liver Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Sep 1:102456.
    >> Share

    August 2024
  46. GANTZEL RH, Deleuran T, Vilstrup H, Watson H, et al
    The CIRrhotic Ascites Severity (CIRAS) model predicts hepatic hydrothorax at all stages of ascites.
    Clin Res Hepatol Gastroenterol. 2024;48:102452.
    >> Share

  47. EZHILARASAN D, Najimi M
    Quiescent hepatic stellate cell activation in liver fibrosis: Have we found the right trigger yet?
    Clin Res Hepatol Gastroenterol. 2024;48:102420.
    >> Share

  48. HU T, Tang W, Hong W, Huang Q, et al
    Spermine oxidase regulates liver inflammation and fibrosis through beta-catenin pathway.
    Clin Res Hepatol Gastroenterol. 2024;48:102421.
    >> Share

  49. LIN YL, Yao T, Wang YW, Yu JS, et al
    Association between primary biliary cholangitis with diabetes and cardiovascular diseases: A bidirectional multivariable Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102419.
    >> Share

  50. LI R, Lee S, Rienas W, Sarin S, et al
    Higher risk of in-hospital mortality and hepatic encephalopathy during weekend admission in Transjugular Intrahepatic Portosystemic Shunt procedure.
    Clin Res Hepatol Gastroenterol. 2024;48:102396.
    >> Share

  51. JIANG R, Hua Y, Hu X, Hong Z, et al
    The pan immune inflammatory value in relation to non-alcoholic fatty liver disease and hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2024;48:102393.
    >> Share

  52. HU J, Mi Y, Wang L, Jiang F, et al
    Exploring the role of mitochondrial proteins SIRT5 and MRPL33 through Mendelian randomization in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102394.
    >> Share

  53. RASHU EB, Werge MP, Hetland LE, Thing M, et al
    Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
    Clin Res Hepatol Gastroenterol. 2024;48:102389.
    >> Share

  54. FU H, Li H, Du Y, Liu C, et al
    Factors influencing pathological changes in the liver tissue in hepatitis B virus carriers with low-level viremia.
    Clin Res Hepatol Gastroenterol. 2024;48:102351.
    >> Share

    July 2024
  55. BALE G, Clarembeau F, Starkel P, Dahlqvist G, et al
    Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Jul 22:102428.
    >> Share

    June 2024
  56. OLIVEIRA M, Gaspar R, Santos L, Macedo G, et al
    High incidence of hepatocarcinoma in patients with advanced fibrosis treated with direct-acting antiviral agents for hepatitis C: a real-world retrospective study.
    Clin Res Hepatol Gastroenterol. 2024 Jun 18:102404.
    >> Share

  57. ROGALSKI J, Czarnecka-Chrebelska K, Weglewska K, Pleska K, et al
    Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients.
    Clin Res Hepatol Gastroenterol. 2024;48:102366.
    >> Share

  58. TANAKA A, Corpechot C
    PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old.
    Clin Res Hepatol Gastroenterol. 2024;48:102358.
    >> Share

  59. ZHOU F, Liu X, Chang C, Liu J, et al
    Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102352.
    >> Share

    May 2024
  60. MANSUR A, Grobman B, Lu CY
    Suicide risk is elevated among patients with chronic liver disease and cirrhosis in the United States.
    Clin Res Hepatol Gastroenterol. 2024;48:102378.
    >> Share

  61. CHANG G, Sun J, Li J, Li T, et al
    Effect of Probiotics on Portal Hypertension (PH) with Cirrhosis: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2024 May 1:102361.
    >> Share

  62. LI R, Sarin S
    The smoker's paradox in transjugular intrahepatic portosystemic shunt procedure: A national inpatient sample analysis from 2015 to 2020.
    Clin Res Hepatol Gastroenterol. 2024;48:102323.
    >> Share

  63. LIANG Y, Li J, Zhang Z, Jiang T, et al
    Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk.
    Clin Res Hepatol Gastroenterol. 2024;48:102321.
    >> Share

    April 2024
  64. PATEL K, Twohig P, Peeraphatdit T, Stohs EJ, et al
    Outcomes and factors associated with cryptococcal disease among cirrhotics: A study of the national inpatient sample 2005 to 2014.
    Clin Res Hepatol Gastroenterol. 2024;48:102337.
    >> Share

    February 2024
  65. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    >> Share

  66. XIE C, Liu K, Xie Y, Liu S, et al
    Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102264.
    >> Share

    January 2024
  67. KUMAR MS
    Paneth cell: The missing link between obesity, MASH and portal hypertension.
    Clin Res Hepatol Gastroenterol. 2024;48:102259.
    >> Share

  68. SEXTON F, Shanahan W, Ryan JD
    Xanthoma striatum palmare: Getting a handle on hyperlipidaemia in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102255.
    >> Share

    December 2023
  69. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    >> Share

  70. JANG H, Han N, Staatz CE, Kwak JH, et al
    Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102227.
    >> Share

  71. JIANG R, Zhou Y, Han L, Hong Z, et al
    Serum vitamin D is associated with ultrasound-defined hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2023;47:102228.
    >> Share

  72. DONATI A, Henrion J, Regnier M, Deltenre P, et al
    Abstinence is associated with better outcomes in patients with alcohol-related hepatocellular carcinoma: Results of an observational study.
    Clin Res Hepatol Gastroenterol. 2023;47:102225.
    >> Share

    October 2023
  73. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    >> Share

  74. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    >> Share

    September 2023
  75. MARTINO VD, Questiaux J, Lemagoarou T, Weil D, et al
    Granulocyte Colony Stimulating Factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: a comprehensive meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2023 Sep 14:102207.
    >> Share

  76. KOUNIS I, Sacleux SC, Ordan MA, Andre S, et al
    Efficiency and safety of total plasma exchange in critically ill cirrhotic patients with acute on chronic liver failure: A pilot study.
    Clin Res Hepatol Gastroenterol. 2023;47:102206.
    >> Share

    August 2023
  77. LU M, Zhu M, Li H, Wang Q, et al
    Factors associated with discordance in the assessment of fibrosis stage between transient elastography and liver biopsy in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102183.
    >> Share

  78. MAMANDIPOOR B, Wernly S, Semmler G, Flamm M, et al
    Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study.
    Clin Res Hepatol Gastroenterol. 2023;47:102181.
    >> Share

  79. CALLERI A, Alessandria C
    Renal damage in Hepatorenal Syndrome: A still unsolved issue.
    Clin Res Hepatol Gastroenterol. 2023;47:102178.
    >> Share

    June 2023
  80. WANG X, Xu GH, Yu J, Li H, et al
    When cirrhosis meets paroxysmal nocturnal hemoglobinuria: What kind of "fireworks" scenario will occur?
    Clin Res Hepatol Gastroenterol. 2023;47:102173.
    >> Share

    May 2023
  81. YAICI L, Gatouillat G, Andreoletti L, N'Guyen Y, et al
    Chronic Hepatitis Delta cirrhosis cured by adapting PEG-IFNalpha-2a + tenofovir disoproxil fumarate treatment duration until HBsAg loss.
    Clin Res Hepatol Gastroenterol. 2023 May 25:102148.
    >> Share

  82. RAVAIOLI F, Berger A, Farcau O, Colecchia A, et al
    Individual and population screening of varices needing treatment by a simple, safe and accurate test.
    Clin Res Hepatol Gastroenterol. 2023;47:102123.
    >> Share

  83. MALKANI KV, Jesudian AB, Luo JJ, Schonfeld EA, et al
    Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102114.
    >> Share

  84. MEURER A, Antoni C, Ebert MP, Trimborn A, et al
    Spontaneous bacterial peritonitis caused by Listeria monocytogenes: A rare infection with very high leukocyte counts in ascitic fluid-case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2023;47:102130.
    >> Share

    April 2023
  85. SASAKI M, Sato Y, Nakanuma Y
    An involvement of Hippo-yes-associated protein pathway in biliary epithelial senescence in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2023;47:102106.
    >> Share

    March 2023
  86. CAO L, Qu N, Wang X, Chen L, et al
    The function of long non-coding RNA in non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102095.
    >> Share

    February 2023
  87. IANNONE G, Pompili E, Renzulli M, Caraceni P, et al
    A case of peri-stomal ectopic variceal bleeding in a patient with decompensated cirrhosis treated with TIPS placement.
    Clin Res Hepatol Gastroenterol. 2023 Feb 24:102098.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016